Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Almonertinib in First-line NSCLC with Poor Performance Status
NCT05826483Phase 1Unknown
- Sponsor
- Guangzhou Institute of Respiratory Health
- Start
- Jan 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of almonertinib in non-small cell lung cancer (NSCLC), sponsored by Guangzhou Institute of Respiratory Health. Primary endpoints: Objective Response Rate at 24 months and Time of Performance Status score change from 2~4 to 1 at 6 months. Status: unknown.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05826483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05826483.